Literature DB >> 7388770

Phase II trial of prednimustine, L-1031, (NSC-134087) in advanced breast cancer.

H T Mouridsen, D Kristensen, J H Nielsen, P Dombernowsky.   

Abstract

The therapeutic effect of prednimustine was studied in 35 patients with advanced breast cancer resistant to previous cytotoxic and/or endocrine therapy. Response (PR + CR) was obtained in 14 patients (40%) of a median duration of five months. Among the 14 responding patients, 10 were resistant to previous endocrine therapy and chemotherapy, in all cases including alkylating agents, and 4 were resistant to previous endocrine therapy. Hematologic toxicity was rather pronounced, but other toxicities were only moderate.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7388770     DOI： 10.1002/1097-0142(19800715)46:2<253::aid-cncr2820460205>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  8 in total

1.  Pharmacokinetics of chlorambucil in man after administration of the free drug and its prednisolone ester (prednimustine, Leo 1031).

Authors:  H Ehrsson; I Wallin; S O Nilsson; B Johansson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.

Authors:  H Samonigg; H Stöger; A K Kasparek; M Schmid; J Dusleag; K Pfeiffer; M Smola; P Steindorfer; P Lechner
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: a phase I-II study.

Authors:  H T Mouridsen; E Boesen
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

4.  Disposition of orally administered 14C-prednimustine in cancer patients.

Authors:  R C Gaver; G Deeb; K A Pittman; B F Issell; A Mittelman; R D Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro.

Authors:  E Musch; M Malek; J Peter-Katalinic; H Egge; H Rink; B Lathan; E Riedel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Prednimustine and vincristine compared with cytosine arabinoside and thioguanine for treatment of elderly patients with acute nonlymphoblastic leukemia.

Authors:  B Lönnqvist; B Andersson; M Björkholm; L Engstedt; G Gahrton; R Hast; G Holm; A Killander; B Lantz; D Lockner; H Mellstedt; J Palmblad; C Paul; C Peterson; B Simonsson; A M Stalfelt; A M Udén; B Wadman; G Oberg
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activity.

Authors:  M E O'Brien; D M Eccles; S G Allen; G Knight; A Rodger; U Chetty; J F Smyth; R C Leonard
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts.

Authors:  D R Gandara; C A Ries; S A Schiff; C B George; J P Lewis; M M Koretz; S K Carter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.